Frontier Biotech announced that the company's exclusive patented product, Aikenin, was successfully discussed and included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue”. Aikonin is the world's first approved long-term HIV fusion inhibitor. It is administered once a week. It has the characteristics of low frequency of use, fast efficacy, high drug resistance barrier, high safety, and few side effects. The medical insurance payment standard maintains the original payment standard of 532 yuan. The limited payment range maintains the original limited payment scope, and limits HIV infection. This medical insurance renewal will benefit the clinical prescriptions of Iconin, help the product sink in local cities and county-level markets, and help the sales and commercialization of subsequent products.